Eden vs Queen RX
Two GLP-1 desks, one scoreboard. We put Eden and Queen RX head-to-head on the published Brief Score — the same six factors, scored the same way.
The verdict
Eden takes this head-to-head.
Eden scores 91 to 68 on our six-factor Brief Score — A polished, high-disclosure program with strong nationwide coverage — you pay more, but you know exactly what you're paying for.
That doesn't make Queen RX a bad call — it's best for readers who want budget-conscious patients seeking low-cost compounded glp-1. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Eden | Queen RX | |
|---|---|---|
| Brief Score | 91/100 (A−) | 68/100 (C) |
| Semaglutide | $239/mo | From $100/mo (quarterly plan, compounded) |
| Tirzepatide | $349/mo | Not disclosed |
| Coverage | All 50 states | 45 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
| On the tracker | Stableprice stable | Newnew to the tracker, no prior reading |
Eden: Premium line steady; high supply-chain disclosure keeps our confidence high.
Queen RX: New to the tracker on 1 August 2026. The published line reads From $100/mo (quarterly plan, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.